AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04073277 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Untreated needles
Description: he untreated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the control groups.
Study NCT00774748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insuflon
Description: Indwelling subcutaneous catheter indicated for subcutaneous infusion of medication by injection. Maximum lifespan: 7 days or 75 injections.
Study NCT04384874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: A 12 week multi-stage exercise rehabilitation program
Study NCT04384874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: A 12 week multi-stage exercise rehabilitation program
Study NCT03331406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Description: 12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.
Study NCT01873885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Single IV (Intravenous) Infusion
Description: 0.9% Sodium Chloride - 30 minute IV infusion
Study NCT01873885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Single IV Infusion Vasomera (PB1046)
Study NCT01855906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gap balanced surgical technique
Description: Gap balanced surgical technique
Study NCT01855906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measured resection
Description: Measured resection surgical technique
Study NCT03462147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulation
Description: Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)
Study NCT03462147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)
Study NCT03462147 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal cord stimulation
Description: Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)
Study NCT03463447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Dynamometer
Description: Mensuration of the handgrip strength of each volunteer using an electronic dynamometer.
Study NCT03463447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydraulic dynamometer
Description: Mensuration of the handgrip strength of each volunteer using a hydraulic dynamometer.
Study NCT02508207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor/Ivacaftor
Description: Tezacaftor/Ivacaftor FDC
Study NCT02508207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study NCT02508207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tezacaftor/Ivacaftor matching placebo
Study NCT02508207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor matching placebo
Study NCT01181128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor VIII (rFVIIIFc)
Study NCT01181128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advate®
Study NCT00662701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.
Study NCT00662701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Ablation
Description: Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
Study NCT02371252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic alendronate
Description: The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.
Study NCT01158586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl
Study NCT01158586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl
Study NCT03913910 — intervention group
Intervention type: PROCEDURE
Intervention: Lipogems
Description: Autologous micro-fragmented adipose tissue is injected in the internal orifice, mucosal, submucosal and muscular layer, then in the fistula tract and external orifice in addition to anal flap.
Study NCT02685865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FCSEM Stent
Description: Hot Axios Fully covered self-expandable metal stent - Boston Scientific
Study NCT02685865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic Stent
Description: 7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
Study NCT03528850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine evaluation
Description: Weekly virtual visits and daily biometric readings of blood pressure, weight, oxygen saturation and pulse
Study NCT03879863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%) QID
Description: Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
Study NCT03879863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution QID
Description: Vehicle Ophthalmic Solution administered QID for twelve weeks
Study NCT03879863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%) QID to BID
Description: Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
Study NCT03879863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution QID to BID
Description: Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
Study NCT03579901 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants
Description: Breast augmentation
Study NCT03370146 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mental training based on Motor Imagery
Description: Patients of the experimental group will be instructed to imagine walking, from a first person perspective, focusing on the kinaesthetic sensations typically associated with the movement. The motor imagery training will be performed using the support of a laptop, on which there will be presented complex static scenes, representing different kind of paths with different landmarks to reach during the mental walking.
Study NCT02648997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab - 240 mg
Description: 240 mg every 2 weeks
Study NCT02648997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab - 1 mg/kg
Description: 1 mg/kg every 3 weeks
Study NCT02648997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab - 480 mg
Description: 480 mg once every 4 weeks
Study NCT02648997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab - 3 mg/kg
Description: 3 mg/kg every 3 weeks
Study NCT02648997 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam RT
Description: IMRT, 3D-CRT, or proton-beam radiation therapy
Study NCT02944617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02944617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02944617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient-Fortified Probiotic Yogurt
Description: Receive Activia yogurt
Study NCT02944617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGF-TKI
Description: Must be received as standard of care chemotherapy
Study NCT02944617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VEGF-TKI
Description: Must be received as standard of care chemotherapy
Study NCT01045018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 400 mg
Study NCT01045018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Study NCT03496415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
Study NCT04827394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neonatal warming mattress
Description: Babies will be warmed with a standard neonatal transport warming mattress immediately after birth.
Study NCT04827394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterile polyethylene wrap
Description: Babies will be wrapped in a sterile polyethylene wrap prior to arrival at the warmer.
Study NCT06209983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS
Description: 1. Preoperative preparation: shorten the fasting time, take a small amount of sugar water two hours before the surgery, and reduce excessive bowel preparation.~2. Intraoperative care: multi-model analgesia (mainly epidural analgesia), sleep depth monitoring, warm air blanket to avoid hypothermia.~3. Postoperative care: focus on pain relief methods (such as oral analgesics, patient-controlled epidural analgesia), early postoperative feeding (try drinking water on the first day after surgery, liquid diet on the second day, and soft diet on the third day), early removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters, and medication to prevent postoperative nausea and vomiting.
Study NCT06209983 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional care
Description: 1. Preoperative preparation: overnight fasting preparation, bowel preparation.~2. Intraoperative care: traditional pain care (intravenous analgesics), sleep depth monitoring, warm air blanket, central venous pressure and body water monitoring indicators, traditional muscle tension relaxation treatment and the use of health insurance antagonist drugs (Neostigmine).~3. Postoperative care: patient-controlled intravenous drip for postoperative pain relief, oral feeing (rice porridge) on the postoperative day 5, and according to the progression of patient condition, step by step to removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters.
Study NCT04499664 — intervention group
Intervention type: DEVICE
Intervention: Monitoring of the autonomic nervous system
Description: Monitoring of the autonomic nervous system using E-patch, LiDCO and Root-Massimo.
Study NCT03370146 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive training
Description: Patients of the control group 1 will undergo a general cognitive training, not based on motor imagery.
Study NCT03370146 — intervention group
Intervention type: BEHAVIORAL
Intervention: Evaluation of gait abilities
Description: All the subjects included in the trial will undergo a series of behavioral test for the evaluation of gai abilities
Study NCT04571021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-DEPT
Description: Implementation of the novel triage algorithm
Study NCT04571021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DEPT
Description: Existing triage algorithm
Study NCT03575585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEST assessment only
Description: Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels.
Study NCT03575585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEST assessment plus feedback report
Description: Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels. Based on their responses they also receive a personalized feedback report that .provides individualized risk levels in five behavior domains: 1) number of partners, 2) riskiness of partners, 3) condom use, 4) riskiness of sex acts, and 5) sex under the influence of drugs or alcohol.
Study NCT03496415 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham remote ischemic conditioning
Description: sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
Study NCT00771875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit Antithymocyte Globulin (RATG)
Description: All patients will receive Thymoglobulin dosed based on CD3 count. Patients will be redosed when the CD3 count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily.
Study NCT00771875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.
Study NCT00771875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.
Study NCT01310738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimoniate of N-methylglucamine
Description: Antimoniate of N-methyl glucamine 20mg/kg/d of pentavalent antimonial, I.V. for 20 consecutive days.
Study NCT01310738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amphotericin B deoxycholate
Description: 1mg/kg/d, I.V. for 14 consecutive days.
Study NCT01310738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Description: 3mg/kg/d, I.V. for 7 consecutive days.
Study NCT01310738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Description: 10mg/kg/d, I.V. single dose.
Study NCT01310738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimoniate of N-methylglucamine
Description: 20mg/kg/d of pentavalent antimonial I.V. for 10 days
Study NCT00765583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane
Description: Treatment of the nasolabial folds with Restylane at Day 0/Baseline, Month 4.5, Month 9 and Month 18.
Study NCT02172118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1774 CL
Study NCT02032628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.
Study NCT04773769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea Made of Graviola Leaves
Description: Graviola leaves will be supplied to the patient with instructions on how to prepare the tea which will consist of 10 guanabana leaves which the patient will boil in 1 liter of water for 3 minutes. Once boiled, the formulation will be stores in the refrigerator and once cool enough the patient will start drinking 100 cc two times per day.~The Treatment Period begins with Cycle 1 Day 1 dosing. Patients will take the tea continuously during a 28-day cycles, until there is an indication for treatment change based on response assessment.
Study NCT02344940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene
Description: patients will take toremifene 60 mg qd.
Study NCT02344940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: patients will take tamoxifen 10 mg bid.
Study NCT03066076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithyroid Drug
Description: Antithyroid drug
Study NCT03066076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy
Description: Operation
Study NCT02739646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional MRI scan
Description: 7.0 Tesla functional MRI scan
Study NCT01601977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVAPS-AE
Description: Novel ventilation mode (Omnilab - AVAPS AE algorithm)
Study NCT00944944 — intervention group
Intervention type: BEHAVIORAL
Intervention: limb volume measurements and GCLQ lymphedema symptom assessment questionnaire
Description: Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
Study NCT00944944 — intervention group
Intervention type: BEHAVIORAL
Intervention: GCLQ lymphedema symptom assessment questionnaire
Description: The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
Study NCT03665155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-daratumumab
Description: 2 mCi of 89Zr-daratumumab will be administered on day 0.
Study NCT01601977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Non-invasive ventilation with standard ventilator
Study NCT01566825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: amitriptyline 25 mg at 9:30 pm, day 10, and 50 mg at 1:30 am, day 11
Study NCT01566825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11
Study NCT03665155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT scans
Description: PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.
Study NCT03665155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,
Study NCT01104272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipoSonix (Ultrasound treatment of Subcutaneous Adipose Tissue)
Description: Study of Adipose Tissue Treatment Using Focused Ultrasound
Study NCT01186419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD602 (FBS0701, SSP-004184)
Description: Oral FBS0701 taken one time daily for up to 96 weeks.
Study NCT02696577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose aspirin
Study NCT02696577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3
Study NCT02450474 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent pneumatic compression device
Description: Flowtron, Circulation Booster and Sports XL devices will be used.
Study NCT02450474 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neuromuscular electrical stimulation
Description: Flowtron, Circulation Booster and Sports XL devices will be used.
Study NCT00749632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin
Description: low dose oxybutynin administered daily
Study NCT00749632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin
Description: middle dose oxybutynin administered daily
Study NCT03942055 — intervention group
Intervention type: DEVICE
Intervention: Sonosite Edge II Ultrasound
Description: Certified by UAB Biomedical and Clinical Engineering Dept- certification #9365 Mechanism of Action: Point of Care Bedside Ultrasound
Study NCT03923842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab Inj 120 MG/1.7ML
Description: Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
Study NCT03923842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy as clinical standard of care
Description: platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Gemcitabine will continue for 12 months if the patient will not shown disease progression
Study NCT01078545 — intervention group
Intervention type: DRUG
Intervention: Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)
Description: Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.